ADMA
NASDAQADMA Biologics Inc
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Website
News25/Ratings9
News · 26 weeks44-69%
2025-10-262026-04-19
Mix3590d
- Insider20(57%)
- SEC Filings6(17%)
- Other5(14%)
- Analyst2(6%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- ANALYSTCanaccord Genuity initiated coverage on ADMA Biologics with a new price targetCanaccord Genuity initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $21.00
- SECSEC Form DEFA14A filed by ADMA Biologics IncDEFA14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECSEC Form DEF 14A filed by ADMA Biologics IncDEF 14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- INSIDERSEC Form 4 filed by Kestenberg-Messina Kaitlin M.4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper ResearchShort seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for – and Utilization of – ASCENIV Has Grown Steadily Over Past Two Years and is at Record High Details that Stocking Levels Maintained by ADMA's Distributors Align with Industry Standards and Reflect the Long Production Cycle for ASCENIV RAMSEY, N.J. and BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company ded
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ADMA Biologics IncSCHEDULE 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
- ANALYSTADMA Biologics downgraded by Cantor FitzgeraldCantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral
- PRADMA Biologics Addresses Misleading Short-Seller ReportRAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the "Short Report"), a firm that has published similarly negative "research reports" regarding public companies after taking short positions in the stock. The Short Report discloses that Culper Research holds a short position in ADMA. ADMA, and its Board of Directors takes seriously its obligations to fairly and accurately report its operating and financial
- INSIDERDirector Guiheen Lawrence P. exercised 30,000 shares at a strike of $3.66, gifted 30,000 shares and received a gift of 30,000 shares (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $318,360 worth of shares (21,000 units at $15.16), decreasing direct ownership by 0.28% to 2,112,777 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERSEC Form 4 filed by ADMA Biologics Inc4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S covered exercise/tax liability with 85,951 shares, decreasing direct ownership by 4% to 2,118,777 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Elms Steve bought $217,420 worth of shares (14,000 units at $15.53) (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S covered exercise/tax liability with 54,858 shares, decreasing direct ownership by 2% to 2,204,728 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase InitiativeRAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase ("ASR") agreement with JPMorgan Chase Bank, National Association ("JPMorgan"). The initiative underscores the Company's strong financial position, durable free cash flow profile and confidence in its long-term growth trajectory. "We believe ADMA's common stock rep
- INSIDERNew insider Kohler Terry claimed ownership of 58,019 shares (SEC Form 3)3 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECSEC Form 10-K filed by ADMA Biologics Inc10-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateFY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo
- INSIDERCOO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 8,161 shares, decreasing direct ownership by 1% to 572,160 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S covered exercise/tax liability with 24,793 shares, decreasing direct ownership by 1% to 2,259,586 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERCFO and Treasurer Tade Brad L. covered exercise/tax liability with 6,479 shares, decreasing direct ownership by 3% to 232,940 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- PRADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial